-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 30, the U.S. Food and Drug Administration approved the new drug Azedra (iobenguane I 131) to treat rare adrenal tumors (chromiocelloma or paraneurotic tumors) intravenously, which has spread beyond the original tumor site and require son-in-the-whole cancer treatment in adults and adolescents aged 12 and over. It is worth mentioning that this is also the first treatment for such rare adrenal tumors.
chrome-cones are rare tumors of the adrenal glands, which are located just above the kidneys and are responsible for producing stress hormones such as epinephrine and norepinephrine. And chrome-chimaloma affects the function of the adrenal glands, leading to excessive production of adrenal hormones, leading to high blood pressure (hypertension) and headache, irritability, sweating, heart rate acceleration, nausea, vomiting, weight loss, weakness, chest pain or anxiety and other symptoms. When this type of tumor occurs outside the adrenal gland, it is called a paraneuroinoma.
this approved Azedra is an innovative radiotherapy drug whose active ingredient iobenguane I 131 selectively targets these rare tumors and kills them. However, because the drug is a radioactive therapeutic agent, patients and their families should be aware of the radiation risk of the drug before taking the drug, especially in pediatric patients at greater risk of radiation exposure."Many patients with super rare tumors can still be treated with surgery or topical therapy," said Dr. Richard Pazdur, director of the FDA'
s Center for Oncology Excellence at the FDA and executive director of the Office of Hematology and Oncology Products at the FDA Center for Drug Evaluation and Research. But patients still lack effective systemic therapies for symptoms such as tumor-related hypertension, and now they have an approved treatment that can be used to lower their blood pressure and reduce the size of tumors in some patients. "(Sun Huan/Compilation)
source: FDA's official website, FDA approves first treatment for rare adrenal tumors,
.
